RxDoctor Payments Data

Aimee Chagnon, MD

Pain Medicine · Sonoma, CANPI 1548450448

Payments from drug & device makers

$812in general payments, 2019–2025

Across 64 payments — averaging $12.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$378
  • Pfizer$277
  • Neurocrine Biosciences, Inc.$35
  • UCB, Inc.$32
  • E.r. Squibb & Sons, L.L.C.$30
  • Biohaven Pharmaceutical Holding Company Ltd.$26
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$78396%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$812 in reported general payments places this provider in the 35th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$114,400
Medicare patients
222
Services billed
981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$233,751
Dimethyl Fumarate17$65,440
Levorphanol Tartrate13$63,697
OxycontinOxycodone Hcl24$59,019
VyeptiEptinezumab-Jjmr12$47,730
RytaryCarbidopa/Levodopa17$29,379
NeuproRotigotine13$27,045
Buprenorphine36$12,864
Emgality PenGalcanezumab-Gnlm16$10,954
Lacosamide81$10,662
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen149$6,920
Oxycodone Hcl170$6,887
ReyvowLasmiditan Succinate12$6,810
Fentanyl47$6,493
Cromolyn Sodium11$6,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Neupro$32$27,04513 claims
Lilly USA, LLCReyvow$14$6,81012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 840 pain medicine providers in California.

Other pain medicine in Sonoma

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →